✨ Medicines and Tax Notices
24 MAY
NEW ZEALAND GAZETTE
1181
Flixotide Rotadisk
Active Ingredient(s): Fluticasone propionate 250µg
Dosage Form: Powder for inhalation
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Production, Evreux, France
Flixotide Rotadisk
Active Ingredient(s): Fluticasone propionate 50µg
Dosage Form: Powder for inhalation
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Production, Evreux, France
Flixotide Rotadisk
Active Ingredient(s): Fluticasone propionate 500µg
Dosage Form: Powder for inhalation
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Production, Evreux, France
Flixotide
Active Ingredient(s): Fluticasone propionate 25µg/dose
Dosage Form: Aerosol inhaler, metered dose
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer(s): Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia
Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom
Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Glaxo Wellcome Production, Evreux, France
Dated this 15th day of May 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3473
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Copaxone
Active Ingredient(s): Glatiramer acetate 20mg
Dosage Form: Powder for injection
New Zealand Sponsor: Aventis Pharma Limited
Manufacturer(s): Teva Pharmaceutical Industries Limited, (Ikapharm) Kfar Saba, Israel
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 16th day of May 2001.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3475
Inland Revenue
Income Tax Act 1994
National Average Market Values of Specified Livestock Determination 2001
This determination may be cited as “The National Average Market Values of Specified Livestock Determination, 2001”.
This determination is made in terms of section EL 8 (1) of the Income Tax Act 1994 and shall apply to specified livestock on hand at the end of the 2000-2001 income year.
For the purposes of section EL 8 (1) of the Income Tax Act 1994, the national average market values of specified livestock for the 2000-2001 income year, are as set out in the following table.
| Type of Livestock | Classes of Livestock | Average Market Value per Head $ |
|---|---|---|
| Sheep | Ewe hoggets | 63 |
| Ram and wether hoggets | 61 | |
| Two-tooth ewes | 72 | |
| Mixed-age ewes (rising three-year and four-year old ewes) | 64 | |
| Rising five-year and older ewes | 54 | |
| Mixed-age wethers | 46 | |
| Breeding rams | 134 | |
| Beef cattle | Beef breeds and beef crosses: | |
| Rising one-year heifers | 423 | |
| Rising two-year heifers | 667 |
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2001, No 52
Gazette.govt.nz —
NZ Gazette 2001, No 52
✨ LLM interpretation of page content
🏥
Consent to the Distribution of Changed Medicines
(continued from previous page)
🏥 Health & Social Welfare15 May 2001
Medicines Act 1981, changed medicines, distribution consent, Flixotide Rotadisk, Fluticasone propionate
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare16 May 2001
Medicines Act 1981, provisional consent, new medicine, Copaxone, Glatiramer acetate
- G. R. Boyd, Chief Advisor, Safety and Regulation
💰 National Average Market Values of Specified Livestock Determination 2001
💰 Finance & RevenueIncome Tax Act 1994, livestock valuation, sheep, beef cattle